Celebrex inhibited the burden of skin cancer in high-risk patients
PHILADELPHIA — People with the heritable disorder of the skin called Gorlin syndrome who are genetically predisposed to develop basal cell carcinoma of the skin may have a new chemoprevention therapy on the horizon.